Clinical Trials

The Harold Schnitzer Diabetes Health Center Research Department is committed to promoting and conducting cutting-edge clinical research. Our goal is to enhance the quality of life of those living with or affected by diabetes.

Our efforts to find a cure for diabetes, and to improve life for people with this condition, are made possible by volunteers who participate in research studies. When you volunteer, you help us answer important questions about diabetes.

If you would like to be considered to participate in any of our research studies below, please call 503 494-4704, complete our Online Application Form for more information.

 

GRADE Study

Study started on: 5/17/13

Currently recruiting patients for this study? Yes

Principal Investigator is Andrew Ahmann, MD

View the Study Brochure

The National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health, in collaboration with 37 medical clinics, including Oregon Health & Science University, is conducting the GRADE Study (The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study). GRADE is a clinical trial designed for people living with diabetes.  The goal of the study is to find the best combination drug treatment for diabetes.

You may qualify for this study, if you:

  • Have had type 2 diabetes for less than 10 years
  • Are taking metformin as your only diabetes medication 

If you join GRADE, you will:

  • Come to Oregon Health & Science University for four diabetes medical visits each year for up to 7  years
  • Take metformin plus one of 4 other diabetes medications chosen by chance
  • Receive diabetes treatment, FDA approved medicines and supplies at no cost to you
  • Receive physical exams and lab tests at no cost to you
  • Receive $100 at the end of each year as well as $10 per visit 
The GRADE Study is being conducted at Oregon Health & Science University.  To learn more about participating in this study, contact: 503 494-4650.

eIRB #9157

 

DIAMOND Study

Currently recruiting patients for this study? Yes
 
Principal Investigator is Andrew Ahmann, MD
 
The OHSU Harold Schnitzer Diabetes Health Center is conducting a research study investigating the value of adding a Continuous Glucose Monitoring System (CGM), and possibly an insulin pump, for persons with diabetes who use multiple daily insulin injections (MDI).
You may be eligible to participate if you:
• Have type 1 or type 2 diabetes
• Are age 25 years or older
• Use at least 3 insulin injections per day
• Have a desire to lower your Hemoglobin A1c (measure of blood sugar control)
 
The study will last up to 7 months for people with type 2 diabetes and up to 13 months for people with type 1 diabetes. All study-related care is provided at no cost to qualified participants including a glucose meter, supplies, and laboratory tests. You will be compensated for participating in the study.

eIRB #11129

 

REPLACE-BG Study

Study started on: 6/2/2015

Currently recruiting patients for this study? Yes

Principal Investigator is Andrew Ahmann, MD

The OHSU Harold Schnitzer Diabetes Health Center is conducting a research study to determine whether it is safe and effective to use the glucose level from a Continuous Glucose Monitor (CGM) to make insulin dosing decisions without confirming the blood sugar level with a blood glucose meter.
 
You may be eligible to participate if you:
  • Have type 1 diabetes for more than 1 and less than 40 years
  • Are age 25 years or older
  • Use an insulin pump for insulin delivery

The study will last up to 9 months. All study-related care is provided at no cost to qualified participants including a glucose meter, supplies, and laboratory tests. You will be compensated for participating in the study.

eIRB #11300


 

TrialNet Study

TrialNet - Pathway to Prevention

Study started on: 2/13/2009

Currently recruiting patients for this study? Yes

Principal Investigator is Andrew Ahmann, MD

The purpose of this study is to learn more about how type 1 diabetes develops in "at-risk" individuals. At risk individuals are those that have a blood relative with type 1 diabetes.

eIRB #5023